Literature DB >> 11300870

Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha.

T A Spencer1, D Li, J S Russel, J L Collins, R K Bledsoe, T G Consler, L B Moore, C M Galardi, D D McKee, J T Moore, M A Watson, D J Parks, M H Lambert, T M Willson.   

Abstract

A cell-free assay was developed for the orphan nuclear receptor LXRalpha that measures the ligand-dependent recruitment of a peptide from the steroid receptor coactivator 1 (SRC1) to the nuclear receptor. Using this ligand-sensing assay (LiSA), the structural requirements for activation of the receptor by oxysterols and related compounds were studied. The minimal pharmacophore for receptor activation was shown to be a sterol with a hydrogen bond acceptor at C24. 24(S),25-Epoxycholesterol (1), which meets this criterion, is among the most efficacious of the oxysterols and is an attractive candidate as the LXRalpha natural hormone. Cholenic acid dimethylamide (14) showed increased efficacy compared to 1, whereas the unnatural oxysterol 22(S)-hydroxycholesterol (4) was shown to be an antagonist of 1 in the LiSA. The structural requirements for SRC1 recruitment in the LiSA correlated with the transcriptional activity of compounds in a cell-based reporter assay employing LXRalpha-GAL4 chimeric receptors. Site-directed mutagenesis identified Trp(443) as an amino acid critical for activation of LXRalpha by oxysterol ligands. This information was combined with the structure-activity relationship developed from the LiSA to develop a 3D homology model of LXRalpha. This model may aid the design of synthetic drugs targeted at this transcriptional regulator of cholesterol homeostasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300870     DOI: 10.1021/jm0004749

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

Review 1.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

Review 2.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

3.  Dietary supplementation with 22-S-hydroxycholesterol to rats reduces body weight gain and the accumulation of liver triacylglycerol.

Authors:  Eili Tranheim Kase; Nataša Nikolić; Nina Pettersen Hessvik; Ase-Karine Fjeldheim; Jørgen Jensen; G Hege Thoresen; Arild C Rustan
Journal:  Lipids       Date:  2012-03-18       Impact factor: 1.880

4.  Biological activities of 7-dehydrocholesterol-derived oxysterols: implications for Smith-Lemli-Opitz syndrome.

Authors:  Zeljka Korade; Libin Xu; Richard Shelton; Ned A Porter
Journal:  J Lipid Res       Date:  2010-08-11       Impact factor: 5.922

5.  Identification of a hormone response element that mediates suppression of APOF by LXR and PPARα agonists.

Authors:  Yan Liu; Lahoucine Izem; Richard E Morton
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-12-06       Impact factor: 4.698

6.  Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation.

Authors:  Stefan Svensson; Tove Ostberg; Micael Jacobsson; Carina Norström; Karin Stefansson; Dan Hallén; Isabel Climent Johansson; Kristina Zachrisson; Derek Ogg; Lena Jendeberg
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

7.  Autoregulation of the human liver X receptor alpha promoter.

Authors:  B A Laffitte; S B Joseph; R Walczak; L Pei; D C Wilpitz; J L Collins; P Tontonoz
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

8.  Oxysterol and 9-cis-retinoic acid stimulate the group IIA secretory phospholipase A2 gene in rat smooth-muscle cells.

Authors:  Valérie Antonio; Brigitte Janvier; Arthur Brouillet; Marise Andreani; Michel Raymondjean
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

9.  Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals.

Authors:  E T Kase; G H Thoresen; S Westerlund; K Højlund; A C Rustan; M Gaster
Journal:  Diabetologia       Date:  2007-07-28       Impact factor: 10.122

10.  Selective partial agonism of liver X receptor alpha is related to differential corepressor recruitment.

Authors:  Caroline A Phelan; Joseph M Weaver; David J Steger; Shree Joshi; Jeffrey T Maslany; Jon L Collins; William J Zuercher; Timothy M Willson; Max Walker; Michael Jaye; Mitchell A Lazar
Journal:  Mol Endocrinol       Date:  2008-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.